The frequency of co-occurrence of Hashimoto disease in granulomatous mastitis patients and its relation to hematological parameters Authors: Buket Altun Özdemir, Servet Kocaöz, Ömer Yazicioğlu, Bülent Çomçali, Furkan Savaş, Onur Karaca, Aysel Çolak, Birol Korukluoğlu Published: 2026 ABSTRACT Background:Idiopathic granulomatous mastitis (IGM) is a benign, chronic inflammatory breast disease frequently associated with autoimmune disorders. This prospective cohort study explored the prevalence of Hashimoto thyroiditis (HT) in patients with IGM and the relationship between this co-occurrence and systemic inflammatory markers.Methods:Between March 2019 and September 2022, 179 women were enrolled: IGM without HT (n = 52), IGM + HT (n = 19), and age-matched healthy controls (n = 89). Hematological indices, including white blood cell count, C-reactive protein, neutrophil-to-lymphocyte ratio (NLR), and lymphocyte-to-monocyte ratio (LMR), were measured at diagnosis before any treatment.Results:The prevalence of HT among patients with IGM was 26.8 %. Compared with isolated IGM, the IGM + HT group had a lower smoking rate (16.3% vs 40.4%, P = .028) and displayed a significantly lower median NLR (1.91 vs 2.76, P < .001) but higher median LMR (6.47 vs 4.75, P = .001).Conclusion:Approximately 1 in 4 women with IGM also had HT. A low NLR-high LMR pattern may reflect a distinct inflammatory milieu in this overlap cohort and could help tailor follow-up strategies for these patients. Routine thyroid screening should be considered in patients with IGM. 1. Introduction Benign and malignant breast diseases have been frequently observed in patients diagnosed with Hashimoto thyroiditis (HT) and nodular goiter.[1–3] Granulomatous mastitis (GM) is recognized as an autoimmune inflammatory disease characterized by chronic granulomatous inflammation of the breast.[4–7] Clinically, GM may present asymptomatically or manifest through breast nodularity, recurrent episodes of mastitis, nipple discharge, nipple retraction, or regional lymphadenopathy.[7] Among GM subtypes, tuberculous mastitis represents the most prevalent form; hence, it is crucial to differentiate it from tuberculosis and breast carcinoma during diagnosis.[8] Furthermore, granulomatous disorders such as Crohn disease, granulomatous polyangiitis (Wegener granulomatosis), sarcoidosis, autoimmune disorders including Immunoglobin G4-related diseases, and systemic lupus erythematosus must be considered during the clinical assessment of GM.[9,10] Crohn disease, although uncommon, classically causes mastitis presenting as breast masses mimicking abscesses and is histologically characterized by granulomatous inflammation with eosinophilic infiltration.[11] The coexistence of HT and GM as secondary autoimmune diseases has been reported in several studies.[7–12] Despite these associations, no study has specifically explored the prevalence of HT in patients with GM. It has been shown that the neutrophil-to-lymphocyte ratio (NLR) is statistically higher in HT cases than in controls. The NLR, a systemic inflammatory biomarker, can be used for the diagnosis and follow-up of HT.[13] Given these inflammatory and autoimmune overlaps, this prospective study aimed to investigate the prevalence of HT in patients diagnosed with idiopathic GM (IGM). Additionally, we evaluated the impact of HT on prognosis and its relationship with systemic inflammatory markers, including the NLR, lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP), in patients with GM. 2. Materials and methods This study is a prospective cohort study conducted from March 1,2019 to September 30,2022 at the Breast and Endocrine Surgery Outpatient Clinic of Ankara City Hospital. Approval was obtained from the Ethics Committee for Clinical Trials of our hospital (E1-20-1415). The inclusion criteria were patients aged > 18 years who were newly diagnosed with GM during the study period. The exclusion criteria were as follows: patients diagnosed before the study date, those whose pathological examinations were performed in other centers, and patients diagnosed with tuberculous mastitis or inflammatory breast cancer. Patients were informed about the study by physicians at the outpatient clinic, and informed consent was obtained from all the participants. One patient with inflammatory breast cancer, 4 with tuberculosis, and 6 who did not wish to participate in the study were excluded. Socio-demographic information, smoking history, family history of granulomatous or autoimmune diseases, and clinical course data were systematically collected. Hematological parameters, including NLR, LMR, PLR, and CRP, were measured at diagnosis before the initiation of any treatment. Whole blood analysis, anti-thyroid peroxidase (TPO), and anti-thyroglobulin (TG) tests were performed on all patients. Thyroid ultrasound was performed exclusively in patients whose anti-TPO or anti-TG levels exceeded the normal laboratory values. The control group was consecutively selected and age-matched, consisting of patients visiting the clinic for benign breast-related concerns without GM or autoimmune thyroid disease. 2.1. Data analysis Data analyses were performed using the SPSS software (version 25.0; IBM Corp.). Numbers, percentages, means, and standard deviations were used to present the descriptive statistical analyses. When the age distribution of patients with and without HT and IGM was analyzed using the Shapiro–Wilk test, the data did not show a normal distribution (P < .001). Similarly, when haematological rates in patients with and without HT and IGM were analyzed using the Shapiro–Wilk test, the data did not show a normal distribution (P < .001). The significance of the difference between haematological rates showing a systemic inflammatory response in patients with and without HT with IGM was analyzed using the Mann–Whitney U test. The significance of the difference in smoking data between patients with and without HT was analyzed using a continuous correction test. The significance of the differences between groups was tested using the Kruskal–Wallis test for haematological parameters in the 3 groups. 3. Results The median age of the patients in the study was 34 years (min: 22–max: 71 years). Smoking was present in 39.4% (n = 28) of patients with IGM. HT occurred in 26.8% of patients with IGM. Among patients with IGM, the median age of patients without HT was 35 years (min: 22, interquartile range [IQR]: 10, max: 71), and the median age of patients with HT was 33 years (min: 23, IQR: 12, max: 59). Among patients with IGM, the median serum anti-TPO level in patients without HT was 28 U/mL (min: 20, IQR: 4, max: 48), and the median anti-TPO level in patients with HT was 253 U/mL (min: 132, IQR: 979, max: 13,000). Among patients with IGM, the median serum anti-TG level in patients without HT was 0.1 IU/mL (min: 0.1, IQR: 0.1, max: 0.4), and the median anti-TG level in patients with HT disease was 1.8 IU/mL (min: 0.6, IQR: 4.39, max: 27.1). Smoking status was significantly lower in patients with IGM and HT (P = .028) (Table 1). The median NLR was 1.91 (min: 1.19, IQR: 0.85, max: 4.09), in patients without HT and 2.76 (min: 1.39, IQR: 1.24, max: 10.5) in patients with coexistence (Fig. 1). The NLR was significantly lower in patients with IGM and concomitant HT (P < .001). The median LMR in patients without HT was 4.75 (min: 2.28, IQR: 2.26, max: 13.88), and the median LMR in patients with coexistence was 6.47 (min: 3.91, IQR: 3.38, max: 20.4) (Fig. 2). The LMR was significantly higher in patients with IGM and concomitant HT (P = .001) (Table 2). Although the percentage of lymphocytes in IGM patients with HT was low, the difference was not statistically significant (P = .225). When only the IGM and IGM + HT groups were compared with the control group, NLR, WBC and CRP levels were significantly higher than in the control group (all P < .001). LMR was significantly lower in the IGM group (P = .001). A significant decrease in hemoglobin was observed in the IGM + HT group (P = .011) (Table 3). Disease recurrence was observed in 19 patients with IGM and in 3 patients with HT (P = .128). Although recurrence was more frequent in smokers, the difference was not statistically significant (P = .075). Table 1Comparison of smoking in patients with and without HT with IGM.IGM HT associationP valueNoYesSmokingNoN16120.028%57.142.9YesN367%83.716.3TotalN5219%73.226.8HT = Hashimoto thyroiditis, IGM = idiopathic granulomatous mastitis, N = number of patients. Comparison of smoking in patients with and without HT with IGM. HT = Hashimoto thyroiditis, IGM = idiopathic granulomatous mastitis, N = number of patients. Table 2Comparison of rates showing systemic inflammatory response in patients with IGM with and without HT.Hematological ratesIGM HT associationNMedianIQRP valueNLRNo522.741.24< .001Yes191.980.84LMRNo524.652.28.001Yes196.453.22PLRNo5214267.77.399Yes19145.6353.56WBCNo529.672.94.018Yes197.922.94CRPNo5210.0015.98.116Yes194.2010.40HbNo5212.801.88.084Yes1912.101.60CRP = C-reactive protein, Hb = hemoglobin, HT = Hashimoto thyroiditis, IGM = idiopathic granulomatous mastitis, IQR = interquartile range, LMR = lymphocyte-to-monocyte ratio, N = number of patients, NLR = neutrophil-to-lymphocyte ratio, PLR = platalet-to-lymphocyte ratio, WBC = white blood count. Comparison of rates showing systemic inflammatory response in patients with IGM with and without HT. CRP = C-reactive protein, Hb = hemoglobin, HT = Hashimoto thyroiditis, IGM = idiopathic granulomatous mastitis, IQR = interquartile range, LMR = lymphocyte-to-monocyte ratio, N = number of patients, NLR = neutrophil-to-lymphocyte ratio, PLR = platalet-to-lymphocyte ratio, WBC = white blood count. Table 3Comparison of the rates of systemic inflammatory response in IGM patients with and without HT with the control group.Hematological ratesIGM HT associationNMedianIQRP ValueNLRIGM522.741.22< .001IGM + HT192.040.85Control892.000.87LMRIGM524.752.38.001IGM + HT196.433.38Control895.741.95PLRIGM52299.50106.75.061IGM + HT19263.0072.00Control89248.0071.00WBCIGM529.652.91< .001IGM + HT197.753.06Control896.752.08CRPIGM5210.0015.98< .001IGM + HT194.2010.40Control894.003.80HbIGM5212.801.88.011IGM + HT1912.101.60Control89131.65CRP = C-reactive protein, Hb = hemoglobin, HT = Hashimoto thyroiditis, IGM = idiopathic granulomatous mastitis, IQR = interquartile range, LMR = lymphocyte-to-monocyte ratio, N = number of patients, NLR = neutrophil-to-lymphocyte ratio, PLR = platalet-to-lymphocyte ratio, WBC = white blood count. Comparison of the rates of systemic inflammatory response in IGM patients with and without HT with the control group. CRP = C-reactive protein, Hb = hemoglobin, HT = Hashimoto thyroiditis, IGM = idiopathic granulomatous mastitis, IQR = interquartile range, LMR = lymphocyte-to-monocyte ratio, N = number of patients, NLR = neutrophil-to-lymphocyte ratio, PLR = platalet-to-lymphocyte ratio, WBC = white blood count. Graph showing the NLR in the blood count of patients with IGM with and without HT. NLR = neutrophil-to-lymphocyte ratio, HT = Hashimoto thyroiditis, IGM = idiopathic granulomatous mastitis. Graph showing the LMR in the blood count of patients with IGM with and without HT. LMR = lymphocyte-monocyte ratio, HT = Hashimoto thyroiditis, IGM = idiopathic granulomatous mastitis. 4. Discussion Smoking is considered one of an etiological factor in IGM. However, the exact association between smoking and IGM remains to be elucidated. Baslaim et al reported no history of smoking among their IGM patients,[14] while other studies have noted varying smoking prevalence ranging from 16.7 to 77.8%.[15,16] Additionally, smoking has been implicated in increased recurrence rates (6–12%).[17,18] Previous studies have also demonstrated that smoking negatively affects thyroid function, influencing iodine uptake and thyroid-stimulating hormone levels,[19,20] exacerbating ophthalmopathy in Grave disease, and increasing relapse rates.[19,21] In our study, smoking prevalence was significantly lower in the group with concurrent IGM and HT compared to those with IGM alone, though the increased recurrence rate in smokers was not statistically significant. Autoimmune thyroid diseases have been associated with lymphocytic mastitis, as evidenced by elevated anti-TPO and anti-TG levels.[12,22] To our knowledge, this study uniquely investigated the prevalence of coexisting HT in patients with IGM, reporting a significantly higher prevalence (26.8%) than that in the general population, which has been reported to range between 5% and 10% in both smaller cohorts and large-scale population-based studies.[23,24] This finding underscores the importance of screening for HT in patients with IGM, as timely detection can facilitate targeted therapeutic interventions and potentially improve patient outcomes. Several studies have highlighted the clinical utility of NLR as an inflammatory biomarker in HT, consistently reporting elevated NLR levels compared to healthy controls.[25–27] CRP, NLR, and PLR have also emerged as potential nonspecific indicators of immune dysregulation in autoimmune diseases, although their precise roles remain unclear.[28,29] In the context of IGM, elevated preoperative NLR values have been linked to disease recurrence.[30–33] However, our study observed a lower NLR and higher LMR in patients with IGM and concurrent HT, suggesting a possible unique inflammatory response in this subgroup. Nevertheless, these results should be interpreted cautiously and considered hypothesis-generating, given the potential confounders such as treatment status and timing of blood sampling. Hematological markers, such as LMR, have demonstrated prognostic value across various diseases, including autoimmune disorders and malignancies, with lower values generally associated with poorer outcomes.[34,35] Although our study identified significant differences in hematological markers, further research is needed to clarify their pathophysiological implications and clinical utility in autoimmune overlap syndromes. Clinically, these findings highlight the potential benefits of routine thyroid screening in patients diagnosed with IGM, considering the high prevalence of coexisting HT. Early recognition of concurrent thyroid diseases may lead to improved management strategies and outcomes. One of the limitations of this study is that it was conducted on patients with IGM who were followed up and treated within a certain period. The advantages of the study are that it consists of patients whose medical records are kept regularly and who are followed up personally by the doctors involved in the study 5. Conclusion This prospective study demonstrated a notably higher prevalence of HT among patients with IGM than in the general population. Patients with coexisting IGM and HT exhibited distinct hematological profiles, including lower NLRs and higher LMRs, suggesting a potentially different immunological response pattern. Although smoking appeared less common in the IGM + HT group and disease recurrence was lower, these associations did not reach statistical significance and warrant further investigation in future studies. From a clinical standpoint, our findings support the potential benefits of routine thyroid screening in patients diagnosed with IGM. Early detection of coexisting thyroid autoimmunity may contribute to more personalized follow-up strategies and improved monitoring of the disease. However, it is important to note that, owing to the observational nature of this study, causal relationships cannot be established. Future multicenter, prospective, and mechanistic studies are needed to confirm these findings and to better understand the immunopathogenic overlap between IGM and autoimmune thyroid disease. Author contributions Data curation: Buket Altun Özdemir, Servet Kocaöz, Ömer Yazicioğlu, Bülent Çomçali, Aysel Çolak. Formal analysis: Buket Altun Özdemir, Servet Kocaöz. Investigation: Servet Kocaöz. Methodology: Servet Kocaöz, Aysel Çolak. Supervision: Onur Karaca, Birol Korukluoğlu. Visualization: Bülent Çomçali. Writing – original draft: Buket Altun Özdemir, Servet Kocaöz, Ömer Yazicioğlu, Bülent Çomçali, Aysel Çolak. Writing – review & editing: Furkan Savaş, Onur Karaca, Birol Korukluoğlu.